Search Videos and More
News
Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians
Dana-Farber Cancer Institute’s Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, was recently elected to one of the nation’s most prestigious medical organizations, The Association of American Physicians (AAP).
News
Stuart Orkin Awarded Breakthrough Prize in Life Sciences
Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor, Harvard Medical School and Investigator, Howard Hughes Medical Institute, has been honored with The Breakthrough Prize in Life Sciences for discovering how the body turns off fetal hemoglobin after birth, a finding that led to a new treatment strategy for sickle cell disease. Dr. Orkin shares the prize with SweeLay Thein, Investigator at the National Institutes of Health (NIH).
News
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.
News
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
Select presentations by Dana-Farber faculty include a promising clinical trial chemotherapy and RAS inhibitor combination for pancreatic patients, new research on mapping the tumor microbiome using the presence of microorganisms and encouraging results from a clinical trial for older patients with multiple myeloma precursor conditions.
News
Immune Activity Shift a Key Early Step in Breast Cancer Formation
Dana-Farber Cancer Institute research provides the first appreciation of the role of special immunosuppressive regulatory T cells in paving a path for precancerous ductal carcinoma in situ (DCIS) to turn into breast cancer.
Document
Treatment Guideline: Vaginal Estrogen in Patients with History of Breast Cancer
The Breast Oncology Center held meetings to discuss recommendations regarding the use of vaginal estrogen in patients with a history of breast cancer.
News
Dana-Farber Research News 04.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.
News
Dana-Farber Researchers Receive AACR 2026 Scientific Achievement Awards
Dr. Eliezer Van Allen and Dr. Kimberly Stegmaier have been selected by the American Association for Cancer Research (AACR) as recipients of 2026 Scientific Achievement Awards. Both researchers will be honored during the AACR Annual Meeting 2026, held April 17-22 at the San Diego Convention Center.
News
The Next Wave of Immune Cell Therapy
From CAR T to eTCR: New immune cell therapies push beyond blood cancers
News
Dana-Farber Research News 04.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 - 15.
News
Dana-Farber Chair of Pathology, Dr. Kathleen Burns, Elected as Fellow of the American Association for the Advancement of Science
Dr. Kathleen Burns, Chair of Pathology at Dana-Farber Cancer Institute, has been named a Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers.
News
Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma
The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.